The evaluation of hormone receptor (HR) status, specifically estrogen receptor (ER) and progesterone receptor (PgR), along with HER2 status, constitutes another essential aspect of BC profiling [17,18,19]. This evidence concerns the gene ESR1 and breast cancer.